Abstract 15912: Cardiac I-123 Metaiodobenzylguanidine Imaging Provides the Additional Prognostic Information to the Model for End-Staged Liver Disease in Patients With Chronic Heart Failure
Backgrounds: Liver dysfunction has a prognostic impact on the outcome of patients with advanced heart failure. A model of end-stage liver disease (MELD) is a robust scoring system of liver dysfunction, and a high score has been shown to be associated with poor prognosis in ambulatory patients with heart failure. In addition, cardiac metaiodobenzylguanidine (MIBG) imaging provides prognostic information in patients with chronic heart failure (CHF). However, the long-term predictive value of combining MELD score and cardiac MIBG imaging in CHF patients has not been elucidated. We sought to investigate whether cardiac MIBG imaging provides additional prognostic information to MELD score in CHF patients.
Methods: We studied 109 CHF outpatients (NYHA class:2.1±0.6, ischemic origin:52%) with left ventricular ejection fraction27%) had a significantly greater risk of the cardiac events than did those with normal WR for both with high MELD score ([[Unable to Display Character: ]]10) (70% [19/27] vs 31% [4/13], p=0.028, hazard ratio 4.0 [95%CI 1.2-13.6]) and low MELD score (<10) (34%[10/29] vs 8%[3/40], p=0.005, hazard ratio 6.4 [95%CI 1.7-23.2]).
Conclusion: Cardiac MIBG imaging would provide the additional prognostic information to MELD score for CHF patients.
Author Disclosures: H. Hakui: None. T. Yamada: None. T. Morita: None. Y. Furukawa: None. S. Tamaki: None. Y. Iwasaki: None. M. Kawasaki: None. A. Kikuchi: None. T. Kondo: None. T. Kawai: None. S. Takahashi: None. M. Ishimi: None. T. Ozaki: None. Y. Sato: None. M. Seo: None. M. Fukunami: None.
- © 2014 by American Heart Association, Inc.